Τίτλος:
Effect of Postablation Statin Treatment on Arrhythmia Recurrence in
Patients With Paroxysmal Atrial Fibrillation
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Statins have been proposed as a means to prevent
postablation atrial fibrillation (AF) recurrences, mainly on the basis
of their pleiotropic effects. The objective of this subanalysis of a
prospectively randomized controlled study population of patients
undergoing radiofrequency ablation for paroxysmal AF was to test the
hypothesis that statin treatment is associated with longer time to
recurrence.
Methods and Results: This is a subanalysis over an extended follow-up
period of a prospective randomized study (ClinicalTrials.gov Identifier
NCT01791699). Among 291 patients, 2 propensity score-matched subgroups
of patients who received or did not receive statins after pulmonary vein
isolation were created. In the unmatched cohort, there was no difference
in the rate of recurrence between statin-treated and not treated
patients, with a 1-year recurrence estimate of 19% and 23%,
respectively (Gehan statistic 0.59, P = 0.443). In the
propensity-matched cohort (N = 166, 83 per group), recurrence-free
survival did not differ significantly between groups (839 days, 95%
confidence interval 755-922 days, in the no statin group vs. 904 days,
95% confidence interval 826-983 in the statin group; P = 0.301). The
1-year recurrence rate estimate was 30% in the no statin group versus
27% in the statin group (Gehan statistic 0.56, P = 0.455).
Conclusion: Statin treatment does not seem to affect AF recurrence in
following radiofrequency ablation for paroxysmal AF, over a follow-up
time of about 2.5 years.
Συγγραφείς:
Giannopoulos, Georgios
Vrachatis, Dimitrios
Kossyvakis,
Charalampos
Angelidis, Christos
Koutivas, Athanasios and
Tsitsinakis, Georgios
Zacharoulis, Achilleas
Kolokathis, Fotios
and Palaiologos, Dimitrios
Vavuranakis, Manolis
Deftereos,
Spyridon
Περιοδικό:
Journal of Cardiovascular Pharmacology
Εκδότης:
Lippincott, Williams & Wilkins
Λέξεις-κλειδιά:
pulmonary vein isolation; radiofrequency; HMG-CoA reductase inhibitor;
recurrence
DOI:
10.1097/FJC.0000000000000624
